Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipid-lowering drugs].

Y Hirakawa1, H Shimokawa

  • 1Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|January 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2).

ESMO gastrointestinal oncology·2026
Same author

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.

ESMO open·2025
Same author

Enhanced expression of nidogen 1 around the nest of basal cell carcinoma compared with that around squamous cell carcinoma.

Medical molecular morphology·2018
Same author

Long-term weight-change slope, weight fluctuation and risk of type 2 diabetes mellitus in middle-aged Japanese men and women: findings of Aichi Workers' Cohort Study.

Nutrition & diabetes·2017
Same author

Endothelial dysfunction and vascular disease - a 30th anniversary update.

Acta physiologica (Oxford, England)·2015
Same author

Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.

Diabetes, obesity & metabolism·2015
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

New lipid-lowering drugs are crucial for preventing atherosclerotic cardiovascular diseases. This review discusses novel statins, ACAT inhibitors, and LPL activators under development in Japan.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Context:

  • Atherosclerotic cardiovascular diseases (ASCVD) pose a significant health burden.
  • Anti-hyperlipidemic treatments are vital for ASCVD prevention.
  • Statins revolutionized hyperlipidemia management since 1989.

Purpose:

  • To review emerging lipid-lowering drugs.
  • To discuss novel agents including statins, ACAT inhibitors, and LPL activators.
  • To highlight drugs under development in Japan.

Summary:

  • Major clinical studies confirm the importance of anti-hyperlipidemic therapy.
  • Lipid-lowering drug classes include statins, resins, nicotinic acid, fibrates, and probucol.
  • New agents like pitavastatin, rosuvastatin, F-1394, CS-505, and NO-1886 are in development.

Related Experiment Videos

Impact:

  • Provides insights into advanced lipid-lowering therapies.
  • Informs on the future direction of cardiovascular disease prevention.
  • Highlights Japan's contribution to novel drug discovery.